Finegoldia magna

(aka Peptostreptococcus magnus)

Bacteria
General | Carbohydrate O/F | Substrate utilisation | Enzymes | Metabolites | Antibiotics

Overview

  • Finegoldia magna, (aka Peptostreptococcus magnus), is a Gram-positive, non-spore-forming, strictly anaerobic, coccus bacterium. It has been detected in at least 23 gut microbiome compilation studies or metastudies. The DNA G+C content is 32–34%. Finegoldia magna is often a widespread coloniser of gut. (Ezaki1983; Murdoch1998a)



  • This organism has been recovered from clinical sources (vagina, abscess, tissue - CCUG) and human faeces. The risk classification (www.baua.de) for this organism is 2, i.e., risk of individual infection, but low risk of spread. It is an opportunistic pathogen. Is a known gut commensal.
    • GENERAL CHARACTERISTICS (Ezaki1983); (Murdoch1998a);
    Character Response
  • Substrates hydrolysed or digested:
  • hippurate;
  • Active enzymes:
  • Ala arylamidase; alkaline phosphatase; esterase lipase C8; Gly arylamidase; Leu arylamidase; Leu-Gly arylamidase; pyrrolidine arylamidase;
    • SPECIAL FEATURES (Ezaki1983); (Murdoch1998a);
    Character Response
  • ✓
  • Metabolites produced:
  • acetate; ammonia;
  • ✗
  • Metabolites not produced:
  • indole;
  • ✗
  • VP test:
  • not active
  • ✗
  • Nitrate:
  • not reduced
    • RESPONSE TO ANTIBIOTICS (Goldstein2003); (Goldstein2018a); (Goldstein2013a); (Goldstein2013b); (Tyrrell2012); (Citron2012a); (Goldstein2008); (Goldstein2006a); (Goldstein2006b); (Goldstein2006c); (Goldstein2005); (Citron2003); (Goldstein2003a); (Citron2001); (Goldstein2000); (Goldstein2000a); (Goldstein1999); (Goldstein1999a); (Goldstein1999b); (Murdoch1998a);
    Class Active Resistant
  • Penicillins:
  • amoxicillin; amoxicillin-clavulanic acid; ampicillin; ampicillin-sulbactam; doripenem; ertapenem; imipenem; meropenem; penicillin; penicillin G; piperacillin-tazobactam; ticarcillin;
  • Cephalosporins:
  • cefotetan; cefoxitin; cefuroxime;
  • cefepime; cefotaxime; ceftazidime;
  • Macrolides:
  • fidaxomicin; pristinamycin; quinupristin-dalfopristin; roxithromycin; telithromycin;
  • clarithromycin;
  • Tetracyclines:
  • doxycycline; minocycline; tetracycline; tigecycline;
  • Quinolines:
  • garenoxacin; gatifloxacin; gemifloxacin; moxifloxacin; sparfloxacin; trovafloxacin;
  • Heterocycles:
  • metronidazole;
  • Vancomycins:
  • vancomycin; dalbavancin; teicoplanin;
  • Miscellaneous antibiotics:
  • clindamycin; daptomycin; linezolid; pristinamycin; ranbezolid; telithromycin;
  • NOTES

    Produces arginine arylamidase, but not proline arylamidase.  Some strains are positive for histidine arylamidase.

  • Finegold, S. M., Howard, R. A., & Vera, L. S. (1974). Effect of diet on human intestinal fecal flora: comparison of Japanese and American diets. Am. J. Clin. Nutr, 27, 1456–1469.

    • Details

    GENERAL
    Lineage Physiology General Growth Tolerances Hydrol./digest./degr.
    Phylum:  Firmicutes Class:  Clostridia Order:  Eubacteriales Family:  Peptoniphilaceae Genus:  Finegoldia Alt. name:  Peptostreptococcus magnus Gram stain:  + O2 Relation.:  strictly anaerobic Spore:  No spore Morphology:  Coccus
    Health:  Unknown
    Source:  clinical sources (vagina, abscess, tissue - CCUG) and human faeces
    DNA G+C(%):  32–34
    		Aesculin:  neg Urea:  neg Gelatin:  vr Hippurate:  + Milk:  neg
    CARBOHYDRATE ACID FORMATION
    Monosaccharide O/F Oligosaccharide O/F Polysaccharide O/F Polyol O/F Other O/F
    Arabinose:  neg L-Arabinose:  neg Fructose:  w Glucose:  neg Mannose:  neg Ribose:  neg D-Tagatose:  neg Xylose:  neg Cellubiose:  neg Lactose:  neg Maltose:  neg Melezitose:  neg Melibiose:  neg Sucrose:  neg Trehalose:  neg Dextrin:  neg Glycogen:  neg Inulin:  neg Starch:  neg D-Arabitol:  neg Mannitol:  neg Sorbitol:  neg
    ENZYME ACTIVITY
    Enzymes: General Enzymes: Carbohydrate Enzymes: Protein Enzymes: Arylamidases Enzymes: Esters/fats
    Catalase:  w Urease:  neg Coagulase:  neg Ac-β-glcamnd:  neg α-Fucosidase:  neg α-Galactosidase:  neg β-Galactosidase:  neg α-Glucosidase:  neg β-Glucosidase:  neg β-Glucuronidase:  neg α-Mannosidase:  neg β-Mannosidase:  neg ArgDH:  vr GluDC:  neg AlanineAA:  + AlaPheProAA:  neg GluGluAA:  neg GlyAA:  + LeuAA:  + LeuGlyAA:  + PyrrolidAA:  + AlkalineP:  + AcidP:  vr Esterase(C4):  vr EstLip(C8):  w(+) Lipase(C14):  neg
    METABOLITES - PRODUCTION & USE
    Fuel Usable Metabolites Metabolites Released Special Products Compounds Produced

    		Acetate:  + Ammonia:  + Indole:  neg
    ANTIBIOTICS ℞
    Penicillins & Penems (μg/mL) Cephalosporins (μg/mL) Aminoglycosides (μg/mL) Macrolides (μg/mL) Quinolones (μg/mL)
    amoxicillin:  S(MIC50): ≤0.125, MIC90: 0.5, RNG: (≤0.125-32)
    Augmentin:  S(MIC50): 0.125, MIC90: 0.5, RNG: (≤0.015-2)
    ampicillin:  S(MIC50): 0.25, MIC90: 1, RNG: (0.06-1)
    amp-sulb:  S(MIC50): 0.12, MIC90: 0.5, RNG: (≤0.03-32)
    penicillin:  S(MIC50): 0.125, MIC90: 0.25, RNG: (0.03–0.5)
    penicillin_G:  S(MIC50): 0.06, MIC90: 0.25, RNG: (≤0.03-0.25)
    piperacillin:  Var(MIC50): 0.12, MIC90: 16, RNG: (≤0.03-64)
    piper-taz:  S(MIC50): ≤0.125, MIC90: 0.5, RNG: (≤0.125-16)
    ticarcillin:  S(MIC50): 0.5, MIC90: 2, RNG: (0.06-128)
    tica-clav:  Var(MIC50): 1, MIC90: 64, RNG: (≤0.03-128)
    doripenem:  S(MIC50): 0.125, MIC90: 0.125, RNG: (0.06–0.125)
    ertapenem:  S(MIC50): 0.125, MIC90: 0.125, RNG: (0.06–0.125)
    imipenem:  S(MIC50): 0.03, MIC90: 0.125, RNG: (≤0.03-0.125)
    meropenem:  S(MIC50): 0.12, MIC90: 2, RNG: (≤0.03-4)
    cefalexin:  Var(MIC50): 2, MIC90: 16, RNG: (0.5->32)
    cefamandole:  Var(MIC50): 2, MIC90: 16, RNG: (0.125-64)
    cefepime:  R(MIC50): 32, MIC90: >32, RNG: (1–>32)
    cefmetazole:  Var(MIC50): 2, MIC90: 32, RNG: (≤0.03-128)
    cefoperazone:  Var(MIC50): 1, MIC90: 128, RNG: (≤0.03->128)
    cefotaxime:  R(MIC50): 8, MIC90: >32, RNG: (1->32)
    cefotetan:  S(MIC50): 0.5, MIC90: 2, RNG: (0.25-2)
    cefotiam:  Var(MIC50): 2, MIC90: 4, RNG: (0.5-16)
    cefoxitin:  S(MIC50): 0.5, MIC90: 1, RNG: (0.06-2)
    ceftazidime:  R(MIC50): 32, MIC90: 64, RNG: (16–64)
    ceftizoxime:  Var(MIC50): 1, MIC90: 8, RNG: (0.06-16)
    cefuroxime:  S(MIC50): 2, MIC90: 8, RNG: (0.25–8)
    moxalactam:  Var(MIC50): 2, MIC90: 8, RNG: (0.06-16)
    azithromycin:  Var(MIC50): 0.25, MIC90: >32, RNG: (≤0.03->32)
    erythromycin:  Var(MIC50): 0.06, MIC90: >32, RNG: (≤0.03->32)
    fidaxomicin:  S(MIC50): 1, MIC90: 2, RNG: (0.25–32)
    clarithromycin:  R(MIC50): >64, MIC90: >64, RNG: (0.03–>64)
    pristinamycin:  S(MIC50): 0.12, MIC90: 0.12, RNG: (0.06–0.12)
    quin-dalf:  S(MIC50): 1, MIC90: 2, RNG: (0.25-2)
    roxithromycin:  S(MIC50): 1, MIC90: 4, RNG: (0.06–>32)
    telithromycin:  S(MIC50): 0.06, MIC90: 0.06, RNG: (0.06–>32)
    linezolid:  S(MIC50): 1, MIC90: 2, RNG: (0.5-2)
    ciprofloxacin:  Var(MIC50): 1, MIC90: 8, RNG: (≤0.5->8)
    garenoxacin:  S(MIC50): 0.125, MIC90: 0.25, RNG: (0.03-0.5)
    gatifloxacin:  S(MIC50): 0.5, MIC90: 2, RNG: (0.125-16)
    gemifloxacin:  S(MIC50): 0.06, MIC90: 4, RNG: (0.03-16)
    levofloxacin:  Var(MIC50): 0.5, MIC90: >8, RNG: (0.25->8)
    moxifloxacin:  S(MIC50): 0.25, MIC90: 4, RNG: (≤0.03-32)
    ofloxacin:  Var(MIC50): 0.25, MIC90: 32, RNG: (0.5-32)
    sparfloxacin:  S(MIC50): 0.5, MIC90: 0.5, RNG: (0.125–0.5)
    trovafloxacin:  S(MIC50): 0.25, MIC90: 0.5, RNG: (0.03-1)
    Tetracyclines (μg/mL) Vancomycin Class (μg/mL) Polypep/ketides (μg/mL) Heterocycles (μg/mL) Other (μg/mL)
    doxycycline:  S(MIC50): 0.125, MIC90: 4, RNG: (0.06–16)
    minocycline:  S(MIC50): 0.125, MIC90: 8, RNG: (0.03–8)
    tetracycline:  S(MIC50): 1, MIC90: 4, RNG: (0.125-32)
    tigecycline:  S(MIC50): 0.25, MIC90: 0.25, RNG: (0.125–0.5)
    dalbavancin:  S(MIC50): 0.06, MIC90: 0.125, RNG: (0.015–0.125)
    teicoplanin:  S(MIC50): 0.125, MIC90: 0.125, RNG: (≤0.006-0.25)
    vancomycin:  S(MIC50): 0.5, MIC90: 1, RNG: (0.25-1)
    bacitracin:  Var(MIC50): 2, MIC90: 32, RNG: (1–32)
    chloramphenicol:  Var(MIC50): 2, MIC90: 8, RNG: (1-32)
    metronidazole:  S(MIC50): 0.25, MIC90: 1, RNG: (0.125-2)
    ranbezolid:  S(MIC50): ≤0.008, MIC90: 0.016, RNG: (≤0.008-0.03)
    clindamycin:  S(MIC50): ≤0.03, MIC90: 0.5, RNG: (≤0.03->32)
    daptomycin:  S(MIC50): 0.5, MIC90: 1, RNG: (0.125-1)

    References

    SPECIFIC REFERENCES FOR FINEGOLDIA MAGNA
  • Goldstein2003 - In Vitro Activities of Daptomycin, Vancomycin, Quinupristin- Dalfopristin, Linezolid, and Five Other Antimicrobials against 307 Gram-Positive Anaerobic and 31 Corynebacterium Clinical Isolates.
  • Ezaki1983 - Transfer of Peptococcus indolicus, Peptococcus asaccharolyticus, Peptococcus prevotii, and Peptococcus magnus to the Genus Peptostreptococcus and Proposal of Peptostreptococcus tetradius sp. nov.
  • Cassir2015 - Clostridium butyricum Strains and Dysbiosis Linked to Necrotizing Enterocolitis in Preterm Neonates
  • Goldstein2018a - Comparative In Vitro Activities of Relebactam, Imipenem, the Combination of the Two, and Six Comparator Antimicrobial Agents against 432 Strains of Anaerobic Organisms, Including Imipenem-Resistant Strains.
  • Goldstein2013a - Comparative in vitro activities of SMT19969, a new antimicrobial agent, against Clostridium difficile and 350 gram-positive and gram-negative aerobic and anaerobic intestinal flora isolates.
  • Goldstein2013b - Comparative in vitro activities of GSK2251052, a novel boron-containing leucyl-tRNA synthetase inhibitor, against 916 anaerobic organisms.
  • Tyrrell2012 - In vitro activity of TD-1792, a multivalent glycopeptide-cephalosporin antibiotic, against 377 strains of anaerobic bacteria and 34 strains of Corynebacterium species.
  • Citron2012a - Comparative in vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria.
  • Goldstein2008 - In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
  • Goldstein2006a - In vitro activity of ceftobiprole against aerobic and anaerobic strains isolated from diabetic foot infections.
  • Goldstein2006b - In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic gram-positive isolates recovered from diabetic foot infections.
  • Goldstein2006c - Comparative in vitro susceptibilities of 396 unusual anaerobic strains to tigecycline and eight other antimicrobial agents.
  • Goldstein2005 - Comparative in vitro activities of XRP 2868, pristinamycin, quinupristin-dalfopristin, vancomycin, daptomycin, linezolid, clarithromycin, telithromycin, clindamycin, and ampicillin against anaerobic gram-positive species, actinomycetes, and lactobacilli.
  • Citron2003 - In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria.
  • Goldstein2003a - In vitro activities of ABT-492, a new fluoroquinolone, against 155 aerobic and 171 anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis.
  • Citron2001 - Comparative in vitro activities of ABT-773 against 362 clinical isolates of anaerobic bacteria.
  • Goldstein2000 - Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens.
  • Goldstein2000a - Comparative In vitro activities of ertapenem (MK-0826) against 1,001 anaerobes isolated from human intra-abdominal infections.
  • Goldstein1999 - In vitro activity of gemifloxacin (SB 265805) against anaerobes.
  • Goldstein1999a - Activity of gatifloxacin compared to those of five other quinolones versus aerobic and anaerobic isolates from skin and soft tissue samples of human and animal bite wound infections.
  • Goldstein1999b - Activities of telithromycin (HMR 3647, RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and other antimicrobial agents against unusual anaerobes.
  • Murdoch1998a - Gram-Positive Anaerobic Cocci.
  • ...............................
    • GUT MICROBIOME COMPILATIONS AND METASTUDIES FOR FINEGOLDIA MAGNA
  • Almeida2019 - A new genomic blueprint of the human gut microbiota.
  • Benno1984 - The intestinal microflora of infants: composition of fecal flora in breast-fed and bottle-fed infants.
  • Benno1986 - Comparison of the fecal microflora in rural Japanese and urban Canadians.
  • Benno1989 - Comparison of fecal microflora of elderly persons in rural and urban areas of Japan.
  • Byrd2020 - Stability and dynamics of the human gut microbiome and its association with systemic immune traits.
  • Cassir2015 - Clostridium butyricum Strains and Dysbiosis Linked to Necrotizing Enterocolitis in Preterm Neonates
  • Dubinkina2017 - Links of gut microbiota composition with alcohol dependence syndrome and alcoholic liver disease
  • Dubourg2013 - The gut microbiota of a patient with resistant tuberculosis is more comprehensively studied by culturomics than by metagenomics.
  • Finegold1974 - Effect of diet on human fecal flora: comparison of Japanese and American diets
  • Finegold1977 - Fecal microbial flora in Seventh Day Adventist populations and control subjects.
  • Forster2019 - A human gut bacterial genome and culture collection for improved metagenomic analyses.
  • Holdeman1976 - Human fecal flora: variation in bacterial composition within individuals and a possible effect of emotional stress.
  • Hu2019 - The Gut Microbiome Signatures Discriminate Healthy From Pulmonary Tuberculosis Patients
  • Lagier2016 - Culture of previously uncultured members of the human gut microbiota by culturomics.
  • New2022 - Collective effects of human genomic variation on microbiome function.
  • Pfleiderer2013 - Culturomics identified 11 new bacterial species from a single anorexia nervosa stool sample.
  • RajilicStojanovic2014 - The first 1000 cultured species of the human gastrointestinal microbiota.
  • Rothschild2018 - Environment dominates over host genetics in shaping human gut microbiota.
  • Tyakht2013 - Human gut microbiota community structures in urban and rural populations in Russia.
  • Walker2011 - High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease.
  • Yang2020 - Species-Level Analysis of Human Gut Microbiota With Metataxonomics.
  • Yang2020a - Establishing high-accuracy biomarkers for colorectal cancer by comparing fecal microbiomes in patients with healthy families
  • Zeller2014 - Potential of fecal microbiota for early-stage detection of colorectal cancer
  • ...............................
    • GENERAL REFERENCES FOR FINEGOLDIA MAGNA
  • Ludwig2009 - Revised road map to the phylum Firmicutes.
    • Added: April 08, 2021